HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

MHRA

Regulatory intelligence
MHRAsafety guidance83% confidence

Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension

Source: MHRA

Why This Matters

Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to elderly patients with osteoporotic vertebral compression fractures.

Regulatory Analysis

The product information has been updated for all domperidone products, to include a contraindication for patients with confirmed or suspected phaeochromocytoma (a rare tumour of the adrenal gland), due to the risk of episodes of severe hypertension.

Supporting Context

Therapeutic area
Orthopedics · Osteoporotic Vertebral Compression Fractures
Sub-indication
General

Related signal: PVP with Pedicle Screw Fixation Shows Superior Outcomes in Elderly Osteoporotic Patients

Source

View source document

Related Signal

Open signal — PVP with Pedicle Screw Fixation Shows Superior Outcomes in Elderly Osteoporotic Patients
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.